Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
HIV
Biotech
Merck's HIV combo treatment meets efficacy bar in phase 3 trials
Two phase 3 studies assessing a combo of Merck's approved doravirine and investigational islatravir met their primary efficacy goals.
Zoey Becker
Dec 19, 2024 11:54am
Jury convicts 2 former biopharma leaders of fraud
Dec 11, 2024 10:26am
Gilead buys HIV vaccine from biotech following clinical collab
Nov 25, 2024 10:30am
Merck-Gilead long-acting oral combo suppresses HIV for 48 weeks
Oct 21, 2024 5:06am
A seventh known patient seems cured of HIV
Jul 18, 2024 1:59pm
GSK sets diversity targets, partners with DEI firm for education
May 22, 2024 11:00am
